Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer	ER-Positive Breast Cancer; HER2-negative Breast Cancer	Recruiting	Phase 2	2026-01-28		NCT05305924

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Eli Lilly and Company	370
The Methodist Hospital Research Institute	124

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Houston Methodist Cancer Center	Houston	United States	18

Clinical trials